Last reviewed · How we verify

ISU Abxis Co., Ltd. — Portfolio Competitive Intelligence Brief

ISU Abxis Co., Ltd. pipeline: 1 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 0 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Cerezyme® Cerezyme® marketed Enzyme replacement therapy Glucocerebrosidase (β-glucosidase) Rare genetic disease / Lysosomal storage disorder
Fabagal® (Agalsidase beta) Fabagal® (Agalsidase beta) phase 3 Enzyme replacement therapy (ERT) α-galactosidase A (GLA enzyme) Rare genetic disease / Lysosomal storage disorder

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Genzyme, a Sanofi Company · 2 shared drug classes
  2. BioMarin Pharmaceutical · 1 shared drug class
  3. Eurofarma Laboratorios S.A. · 1 shared drug class
  4. JCR Pharmaceuticals Co., Ltd. · 1 shared drug class
  5. Masonic Cancer Center, University of Minnesota · 1 shared drug class
  6. Pfizer Inc. · 1 shared drug class
  7. Protalix · 1 shared drug class
  8. Sanofi · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for ISU Abxis Co., Ltd.:

Cite this brief

Drug Landscape (2026). ISU Abxis Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/isu-abxis-co-ltd. Accessed 2026-05-16.

Related